Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay services for quantifying Brain-Derived Tau (BD-Tau) in plasma, serum, cerebrospinal fluid (CSF), and brain tissue lysates down to sub-picogram per milliliter detection limits.
By utilizing specialized monoclonal antibodies that selectively bind CNS-specific tau fragments while completely ignoring non-brain peripheral total Tau background, our Simoa BD-Tau service establishes an etiology-specific fluid biomarker readout for tracking pure central neuroaxonal degeneration in preclinical Alzheimer's disease, acute neurotrauma, and translational neuroscience pipelines.
Establishing standardized bioanalytical parameters to ensure high data integrity across central neuroaxonal breakdown cascades.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Biomarker Role in ATN | BD-Tau as central neurodegenerative endpoint (N) vs. phospho-tau (T: p217/p181) | Disentangles active structural neuroaxonal cytolysis from upstream amyloid-induced phosphorylation. |
| Baseline & Longitudinal Timing | Pre-treatment baselines vs. acute post-trauma (Day 1–7) or progressive chronic drift | Aligns blood draws with central tau clearance kinetics across disease progression. |
| Comparative Multi-Marker Strategy | Pairing BD-Tau with Simoa NfL (axonal caliber) and glial fibrillary acidic protein (GFAP, astrogliosis) | Maps cortical non-myelinated axonal damage (BD-Tau) alongside subcortical myelinated damage (NfL). |
| Micro-Volume Allocation | 15 μL net volume per well, duplicate verification reserve, and orthogonal follow-up | Conserves longitudinal small-animal biofluids across extended preclinical therapeutic regimens. |
| Plate Layout & Balancing | Randomizing treatment arms, dose escalations, and serial timepoints across analytical runs | Eliminates confounding between true experimental treatment effects and run-to-run bioanalytical variance. |
Validated singleplex and multiplex digital immunoassay configurations for ultra-sensitive tau bioanalysis.
| Biomarker Target | Epitope & Specificity Focus | Functional LLOQ (pg/mL) | Dynamic Range (pg/mL) | Primary Focus |
|---|---|---|---|---|
| Brain-Derived Tau (BD-Tau) | Central brain-specific tau fragments | 0.020 | 0.020 – 1,000 | Pure central neurodegeneration, eliminating peripheral tissue background in blood |
| Phospho-Tau 217 (p-Tau217) | Phosphorylated Thr217 (ALZpath configuration) | 0.010 | 0.010 – 500 | Benchmark blood surrogate of cortical amyloid plaque accumulation and tangle seeding |
| Phospho-Tau 181 (p-Tau181) | Phosphorylated Thr181 | 0.050 | 0.050 – 800 | Established clinical research standard for AD baseline cohort characterization |
| Phospho-Tau 231 (p-Tau231) | Phosphorylated Thr231 | 0.030 | 0.030 – 500 | Incipient seeding phase marker, rising during earliest soluble amyloid oligomerization |
| Total Tau (t-Tau) | Pan-tau epitope recognition | 0.050 | 0.050 – 1,200 | Acute structural damage, stroke, severe traumatic brain injury (TBI), and in vitro neuronal cell culture release |
| Simoa N4PD Multiplex Panel | BD-Tau + NfL + GFAP + UCH-L1 (ubiquitin C-terminal hydrolase L1) | 0.020 – 1.80 | 0.020 – 2,000 | Synchronized 4-plex profiling: CNS axonal loss (BD-Tau), structural injury, and gliosis |
Evaluating analytical performance, CNS specificity, sample consumption, and detection boundaries across bioanalytical platforms.
| Technical Dimension | Conventional Total Tau ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa BD-Tau |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | >15.0 pg/mL | 2.0 – 10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.010 – 0.050 pg/mL (Sub-pg/mL) |
| CNS vs. Peripheral Specificity | None (High peripheral noise) | None (Total tau only) | None (Total tau only) | 100% Brain-Derived Specificity |
| Blood-to-CSF Correlation | Poor (r ≈ 0.30–0.45) | Moderate (r ≈ 0.50) | Moderate (r ≈ 0.55) | Exceptional (r = 0.85–0.92) |
| Sample Consumption per Test | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Linear Dynamic Range | 2.0 logs | 3.0 – 3.5 logs | 3.5 – 4.0 logs | >4.5 logs (Poisson digital + Analog) |
| Serial Rodent Survival Bleeds | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Fit | High-titer cell supernatants | Broad screening cohorts | CSF, post-mortem brain tissue | Peripheral blood (serum/plasma), CSF |
Cross-platform transitions from legacy Total Tau ELISA, Luminex, or MSD systems to digital Simoa BD-Tau require structured bioanalytical method bridging. Because BD-Tau specifically eliminates peripheral tau background, absolute values in blood will show a distinct physiological baseline shift while demonstrating substantially higher correlation with paired CSF data.
Our Bridging Protocol: We test a representative pilot subset (15–20 paired baseline and elevated research specimens) in parallel across both platforms to establish a validated mathematical conversion equation, ensuring longitudinal dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters established according to rigorous fit-for-purpose biomarker validation guidelines.
Monoclonal antibody pair specifically recognizes brain-derived tau fragment junctions while completely ignoring non-brain peripheral tau isoforms expressed in peripheral organs.
Validated negative selection demonstrating absence of cross-reactivity with peripheral tau from salivary gland, liver, kidney, and peripheral nerve homogenates.
Direct quantitative correlation (r = 0.85–0.92) between blood BD-Tau and paired CSF Total Tau, resolving the historical discordance of plasma Total Tau assays.
Barcode verification on dry ice, assessment for hemolysis/lipemia, cataloged into monitored -80°C biobanking.
Automated liquid handling performs 1:4 dilution in matrix-matched diluent supplemented with heterophilic blocking agents.
Capture antibodies specific to brain-derived tau epitopes bind target fragments on beads, followed by biotinylated detector binding and SBG labeling.
Bead-enzyme complexes are loaded into 216,000 microwells on Simoa discs, oil-sealed, and imaged for digital Poisson counting (AEB).
Software algorithms interpolate AEB values against calibration curves to output absolute pg/mL concentrations, replicate CVs, and QC metrics.
Standardized pre-analytical protocols ensuring BD-Tau stability and eliminating matrix-induced suppression.
| Pre-Analytical Parameter | Why It Matters for Brain-Derived Tau | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Heparin causes polyanionic interference; K2-EDTA preserves antigen stability and minimizes matrix background. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted for 30–60 min at RT and promptly centrifuged. |
| Centrifugation Protocol | Delayed separation causes non-specific platelet degranulation and microparticle accumulation. | Centrifuge at 2,000 × g for 15 min at 4°C within 60 minutes of collection; harvest platelet-poor plasma. |
| Protease & Phosphatase Control | Brain lysates and tissue homogenates contain active enzymes that cleave tau junctional epitopes. | Supplement lysis buffers with broad-spectrum protease and phosphatase inhibitors (PMSF, EDTA, NaF). |
| Freeze-Thaw Management | Repeated freeze-thaw cycles promote conformational degradation and antibody binding loss. | Aliquot immediately into polypropylene cryovials; store at -80°C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input, conserving small-animal biofluids. | 15 μL net volume per well (30–50 μL recommended for duplicate verification and reserve). |
Applying ultra-sensitive single-molecule BD-Tau measurements across Alzheimer's modeling and neurodegeneration evaluation.
Measure Alzheimer's-type cortical neurodegeneration in blood without confounding from peripheral tissue total tau background.
Track cortical neuronal loss and correlate circulating BD-Tau with post-mortem stereological cortical neuron counts.
Disentangle central neuroprotective drug efficacy from peripheral organ exposure in preclinical candidate screening.
Quantify acute cortical axonal shedding following closed-head impact or rotational acceleration neurotrauma.
Utilize BD-Tau as an objective fluid surrogate for longitudinal MRI cortical thinning in translational neuroscience models.
Pair BD-Tau ("N") with Simoa p-Tau217 ("T") and Simoa NfL for comprehensive neurodegenerative deconvolution.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies establishing Brain-Derived Tau as a central-specific fluid biomarker.
Study Design Takeaway: Seminal paper demonstrating that brain-derived tau (BD-Tau) selectively captures central neurodegeneration in blood, correlating with CSF Total Tau (r = 0.85) while avoiding non-brain peripheral total Tau confounding.
Study Design Takeaway: Establishes the foundational physics of digital Poisson single-molecule enzyme counting in femtoliter microwells, demonstrating up to 1000-fold sensitivity gains over conventional ELISA.
Study Design Takeaway: Details the automated instrument engineering and single-molecule accuracy of dye-encoded magnetic beads in digital immunoassay bioanalysis.
Study Design Takeaway: Validates the temporal hierarchy of tau biomarkers and highlights the synergistic value of pairing early phospho-tau (p231/p217) with structural neurodegenerative markers (BD-Tau/NfL).
Addressing common bioanalytical and project planning inquiries.
Total Tau assays measure all circulating tau isoforms, including peripheral tau released by liver, kidney, and peripheral nerves, resulting in high background noise and weak blood-to-CSF correlation in blood samples. BD-Tau utilizes specific antibodies targeting brain-specific tau fragments, eliminating non-brain background and achieving strong correlation (r > 0.85) with paired CSF Total Tau.
Because blood BD-Tau specifically reflects central cortical neuroaxonal injury without peripheral interference, it correlates directly with cognitive decline, brain atrophy, and post-mortem neurofibrillary tangle pathology. Conventional plasma Total Tau assays frequently show overlapping values between healthy controls and diseased cohorts.
In the ATN framework, amyloid is "A" (Aβ42/40), phosphorylated tau is "T" (p-Tau217/p-Tau181), and neurodegeneration is "N". BD-Tau serves as a highly specific "N" marker for central cortical neuroaxonal loss, complementing Simoa NfL (which reflects subcortical large myelinated axonal degradation).
The standard protocol requires only 15 μL of neat sample volume per well (which is diluted 1:4 on-board to a 60 μL working volume). We recommend providing 30–50 μL total volume to support dead volume and duplicate verification.
No. Because BD-Tau specifically eliminates peripheral non-brain tau background, absolute baseline concentrations in blood are lower and more clinically meaningful than Total Tau ELISA values. We provide paired bridging studies to establish mathematical conversion algorithms for long-term programs.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×